In the last trading session, 0.99 million C4 Therapeutics Inc (NASDAQ:CCCC) shares changed hands as the company’s beta touched 2.98. With the company’s per share price at $2.79 changed hands at -$0.1 or -3.46% during last session, the market valuation stood at $196.94M. CCCC’s last price was a discount, traded about -325.81% off its 52-week high of $11.88.
Analysts gave the C4 Therapeutics Inc (CCCC) stock a consensus recommendation rating of Hold, calculated at a mean rating of 1.80. If we narrow down to specifics, the data shows that 0 out of 3 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 2 recommended CCCC as a Hold, 1 felt it is a Buy and 0 rated the stock as Underweight. C4 Therapeutics Inc’s EPS for the current quarter is expected to be -0.45.
C4 Therapeutics Inc (NASDAQ:CCCC) trade information
Instantly CCCC was in red as seen at the end of in last trading. With action -6.06%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -22.50%, with the 5-day performance at -6.06% in the red. However, in the 30-day time frame, C4 Therapeutics Inc (NASDAQ:CCCC) is -23.14% down.
The consensus price target for the stock as assigned by Wall Street analysts is 16, meaning bulls need an upside of 82.56% from its current market value. According to analyst projections, CCCC’s forecast low is 12 with 20 as the target high. To hit the forecast high, the stock’s price needs a -616.85% plunge from its current level, while the stock would need to soar -330.11% for it to hit the projected low.
C4 Therapeutics Inc (CCCC) estimates and forecasts
Year-over-year growth is forecast to reach 72.35% up from the last financial year.
Consensus estimates given by 7 financial analysts project the company’s revenue in the current quarter to hit an average of 4.43M. 3 analysts are of the opinion that C4 Therapeutics Inc’s revenue for the current quarter will be 3.33M. The company’s revenue for the corresponding quarters a year ago was 3.26M and 3.04M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 35.80%. The estimates for the next quarter sales put growth at 9.69%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -36.05%. The 2025 estimates are for C4 Therapeutics Inc earnings to increase by 44.17%, but the outlook for the next 5-year period is at 12.86% per year.
CCCC Dividends
C4 Therapeutics Inc is expected to release its next quarterly earnings report in March.
RA CAPITAL MANAGEMENT, L.P. holds the second largest percentage of outstanding shares, with 7.0891% or 4.88 million shares worth $22.54 million as of 2024-06-30.
Among Mutual Funds, the top two as of Dec 31, 2024 were Wasatch Ultra Growth Fund and Vanguard Total Stock Market Index Fund . With 3.38 shares estimated at $9.44 million under it, the former controlled 4.79% of total outstanding shares. On the other hand, Vanguard Total Stock Market Index Fund held about 3.03% of the shares, roughly 2.14 shares worth around $5.96 million.
